Researchers have depicted ICBs-induced changes in the immune microenvironment at gene level using single-cell sequencing of pre- and post-treatment biopsies from patients receiving anti-PD1 or anti-PD-L1 therapy in multiple tumor types, including melanoma, basal or squamous cell carcinoma, and breast cancer10–13. Here, CD274 is linked to neoplasm.